Cocrystal Pharma (NASDAQ:COCP) Shares Up 2% – Should You Buy?

Cocrystal Pharma, Inc. (NASDAQ:COCP)’s stock price traded up 2% during mid-day trading on Monday . The stock traded as high as $1.0338 and last traded at $1.03. 48,239 shares changed hands during mid-day trading, an increase of 32% from the average session volume of 36,633 shares. The stock had previously closed at $1.01.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $6.00.

Cocrystal Pharma Stock Up 2.0%

The company has a 50 day moving average of $1.02 and a 200 day moving average of $1.12. The stock has a market capitalization of $14.19 million, a price-to-earnings ratio of -1.10 and a beta of 1.18.

Insider Activity at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost acquired 50,000 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was bought at an average price of $0.95 per share, with a total value of $47,500.00. Following the purchase, the director directly owned 1,888,551 shares in the company, valued at $1,794,123.45. The trade was a 2.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have bought 185,000 shares of company stock worth $177,450. Corporate insiders own 28.14% of the company’s stock.

Institutional Investors Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC purchased a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). 6.72% of the stock is owned by institutional investors and hedge funds.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.